Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial).

By O. Cornely, J. Maertens, M. Bresnik, R. Ebrahimi, A. Ullmann, E. Bouza, C. Heussel, O. Lortholary, C. Rieger, A. Boehme and 9 more. Clinical Infectious Diseases, 2007

678 citations recorded by the source corpus.

Subfields: Infectious Diseases, Public Health, Environmental and Occupational Health

View Paper: https://www.semanticscholar.org/paper/5ab28e0a02adcb30fb1703f20ae732ec317cdaf4

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Infectious Diseases

1. D. Kontoyiannis
2. J. Perfect
3. E. Anaissie
4. M. Pfaller
5. D. Diekema

Citations in the corpus

• ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients (2016, background): “The ECIL Aspergillus recommendations are restricted to hematologic patients who represent more than 90% of the patients included in the major clinical trials.(41,43,50,51) No subgroup of hematologic patients deserving specific recommendation for Aspergillus infection treatment has been identified by”
• Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. (2008, background): “The following FDA-approved compounds have in vitro, in vivo, and clinical activity against Aspergillus species and are licensed for treatment of invasive aspergillosis: D-AMB and its lipid formulations (AMB lipid complex [ABLC], L-AMB, and AMB colloidal dispersion [ABCD]), itra-conazole, voriconazol”
• Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. (2008, background): “Indeed, the definitions were modified to allow enrollment of similar cases into clinical trials, because they are considered to represent likely invasive fungal disease even without supporting mycological evidence [2, 16].”
• Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. (2010, background): “Therapy for presumed aspergillosis (for cases with typical infiltrates on CT) could consist of either voriconazole or liposomal amphotericin B [I, A] [29, 30].”